BioCentury | Sep 13, 2012
Cover Story

VEGF reflects on itself

...d-protein ligand that blocked the binding of VEGF to its receptor in vitro . 1 Reflexion Pharmaceuticals Inc....
...Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Ontario Institute for Cancer Research , Toronto, Ontario, Canada Reflexion Pharmaceuticals Inc....
BioCentury | Sep 13, 2012
Distillery Therapeutics

Indication: Ophthalmic disease

...l-stereoisomer of VEGF-A and prevented it from binding the VEGF receptor (VEGFR). Next steps at Reflexion Pharmaceuticals Inc....
...1). SciBX 5(36); doi:10.1038/scibx.2012.961 Published online Sept. 13, 2012 Findings patented; available for licensing from Reflexion Pharmaceuticals...
Items per page:
1 - 2 of 2
BioCentury | Sep 13, 2012
Cover Story

VEGF reflects on itself

...d-protein ligand that blocked the binding of VEGF to its receptor in vitro . 1 Reflexion Pharmaceuticals Inc....
...Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Ontario Institute for Cancer Research , Toronto, Ontario, Canada Reflexion Pharmaceuticals Inc....
BioCentury | Sep 13, 2012
Distillery Therapeutics

Indication: Ophthalmic disease

...l-stereoisomer of VEGF-A and prevented it from binding the VEGF receptor (VEGFR). Next steps at Reflexion Pharmaceuticals Inc....
...1). SciBX 5(36); doi:10.1038/scibx.2012.961 Published online Sept. 13, 2012 Findings patented; available for licensing from Reflexion Pharmaceuticals...
Items per page:
1 - 2 of 2